Hepatology Unit, Department of Medical & Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Viruses. 2022 Jun 24;14(7):1376. doi: 10.3390/v14071376.
More than 250 million people worldwide are currently infected with hepatitis B, despite the effectiveness of vaccination and other preventive measures. In terms of treatment, new therapeutic approaches are rapidly developing, promising to achieve the elimination of infected cells and the complete cure of infection. The on-treatment monitoring of these innovative antiviral treatments will require the implementation of new virological tools. Therefore, new biomarkers are being evaluated besides the traditional virological and serological assays in order to obtain information on different steps of the viral replication cycle and to monitor response to therapy more accurately. The purpose of this work is to describe both standard and innovative tools for chronic hepatitis B treatment monitoring, and to analyse their potential and feasibility.
尽管疫苗接种和其他预防措施有效，但目前仍有超过 2.5 亿人感染乙型肝炎。在治疗方面，新的治疗方法正在迅速发展，有望实现感染细胞的消除和感染的完全治愈。这些创新抗病毒治疗的治疗中监测将需要实施新的病毒学工具。因此，除了传统的病毒学和血清学检测外，还在评估新的生物标志物，以获得有关病毒复制周期不同步骤的信息，并更准确地监测治疗反应。这项工作的目的是描述慢性乙型肝炎治疗监测的标准和创新工具，并分析它们的潜力和可行性。
